M. Cobo

TL;DR: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin, and a multibiomarker profile predictive of patient outcome is refined.

TL;DR: The high concordance, specificity, and sensitivity demonstrate that EGFR mutation status can be accurately assessed using circulating-free tumor DNA, suggesting that plasma is a suitable substitute for mutation analysis, and tumor tissue should remain the preferred sample type when available.

TL;DR: Treatment with durvalumab resulted in a numerically reduced risk of death vs chemotherapy in patients with programmed cell death ligand 1 expression on at least 25% of tumor cells, highlighting the need for further investigation and prospective validation of blood tumor mutational burden as a predictive biomarker for immunotherapy.

TL;DR: First-line gefitinib was effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC and plasma samples could be considered for mutation analysis if tumour tissue is unavailable.